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Human cytochrome P450 46A1 (CYP46A1) is one of the key
enzymes in cholesterol homeostasis in the brain. The crystal-
lization and heavy-atom structure solution of an active
truncated CYP46A1 in complex with the high-afﬁnity
substrate analogue cholesterol-3-sulfate (CH-3S) is reported.
The 2.6 A ˚ structure of CYP46A1–CH-3S was solved using
both anion and cation heavy-atom salts. In addition to the
native anomalous signal from the haem iron, an NaI anion
halide salt derivative and a complementary CsCl alkali-metal
cation salt derivative were used. The general implications of
the use of halide and alkali-metal quick soaks are discussed.
The importance of using isoionic strength buffers, the titration
of heavy-atom salts into different ionic species and the role of
concentration are considered. It was observed that cation/
anion-binding sites will occasionally overlap, which could
negatively impact upon mixed RbBr soaks used for multiple
anomalous scatterer MAD (MMAD). The use of comple-
mentary cation and anion heavy-atom salt derivatives is a
convenient and powerful tool for MIR(AS) structure solution.
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1. Introduction
Cytochrome P450s (P450 or CYP) constitute a huge super-
family of more than 6500 enzymes that are found in almost all
organisms(http://drnelson/utmem.edu/CytochromeP450.html).
These proteins play key roles in the biotransformation of
various xenobiotics and endobiotics and catalyze several types
of reactions, with the most common being monooxygenation
(Guengerich, 2001). There are 57 P450 genes in humans, which
belong to 18 families and 43 subfamilies
1. 15 human P450s
primarily catalyze the transformation of various xenobiotics,
such as drugs, carcinogens and environmental pollutants. 14
are involved in cholesterol, bile acid or steroid synthesis, four
are primarily involved in the metabolism of vitamins A and D
and nine are involved in the metabolism of eicosanoids and
fatty acids. The roles of the remaining 14 have not yet been
established (Guengerich, 2005). Currently, the structures of 11
different mammalian P450s have been deposited in the PDB.
Of these, one belongs to family 1 (1A2), eight to family 2
(2A6, 2A13, 2B4, 2C5, 2C8, 2C9, 2D6 and 2R1), one to family
3 (3A4) and one to family 8 (8A1). The structurally char-
acterized P450s have a similar overall fold, but have varying
topologies of the active site in order to accommodate different
1 Designation into families and subfamilies is based on amino-acid sequence
identity (Nelson et al., 1996). Enzymes that share >40% identity are assigned
to the same family, designated by an Arabic numeral followed by a letter
indicating the subfamily to which the P450 belongs. Enzymes within
subfamilies are also numbered, usually in the order in which they were
discovered. Sequence identity within subfamilies is >55%.substrates (Li & Poulos, 2004; Johnson & Stout, 2005; Graham
& Peterson, 1999). Even with the same P450, the shape of the
active site can vary signiﬁcantly with different ligands, the
quintessential example being the several structures of
CYP2B4 (Zhao et al., 2006, 2007; Scott et al., 2003, 2004). The
CYP46 gene family has never been crystallized before and is
only distantly related to other structurally characterized
P450s. The crystal structure of CYP46A1 is the ﬁrst of a P450
for which the primary role is cholesterol hydroxylation.
1.1. CYP46A1
CYP46A1 catalyzes the conversion of cholesterol to 24(S)-
hydroxycholesterol (24OH-CH), the ﬁrst step in the major
pathway for cholesterol elimination from the brain (Lund et
al., 1999; Lutjohann et al., 1996). CYP46A1 was also found to
be expressed in the retina (Bretillon et al., 2007). However, the
physiological role of CYP46A1 in the retina still remains to be
established. Evidence has recently been obtained in mice
indicating that side-chain oxidized oxysterols, including
24OH-CH, may be important in vivo ligands for the liver X
receptors, which function as transcription factors for a number
of genes that are involved in lipid metabolism (Chen et al.,
2007; Chawla et al., 2001). Individuals with a complete lack of
cholesterol 24-hydroxylation have not been identiﬁed. The
phenotype of CYP46A1 gene-knockout mice provides some
insight. These animals show severe deﬁciencies in spatial,
associative and motor learning (Kotti et al., 2006), suggesting
that CYP46A1 may also be involved in cognitive function in
humans. Polymorphisms in the CYP46A1 gene are frequent
and some could be associated with Alzheimer’s disease. 13
published papers have suggested that CYP46A1 is a risk factor
for Alzheimer’s disease, while eight papers do not support this
association (reviewed in Pikuleva, 2006; Ma et al., 2006;
Helisalmi et al., 2006; Li et al., 2006; Tedde et al., 2006; Wang &
Jia, 2007). In healthy people, CYP46A1 immunoreactivity is
predominantly conﬁned to neurons, whereas in patients with
Alzheimer’s disease its expression is also detected in astro-
cytes (Brown et al., 2004; Bogdanovic et al., 2001). The
mechanism and signiﬁcance of this shift in the expression
pattern are currently unclear. Cholesterol-3-sulfate (CH-3S),
which we used for cocrystallization with CYP46A1, is a
naturally occurring steroid that is present in many tissues,
including the brain (Liu et al., 2003; Iwamori et al., 1976; Strott
& Higashi, 2003). This steroid sulfate is suggested to have
many cellular functions, including regulation of lipid meta-
bolism (Strott & Higashi, 2003). Until this study, it was not
known that CYP46A1 could bind and metabolize CH-3S in
vitro. Further research is needed to evaluate whether this in
vitro activity is of physiological relevance.
1.2. Halide and alkali-metal salt derivatives
The use of halide salts as anionic heavy-atom derivatives
has been well documented by Dauter and coworkers (Dauter
et al., 2000; Nagem et al., 2003; Dauter & Dauter, 2006).
However, the use of halide-salt quick soaks does not seem to
have become as widespread as one might expect given the
simplicity of the method. The Rb salt used by Korolev and
coworkers in their MAD solution of the hsp60 apical domain
(Korolev et al., 2001) indicated that a heavy-atom cation alkali-
metal salt could be used as a general and nonspeciﬁc heavy-
atom derivative in the same way that halide salts have been
used. The efﬁcacy of cation salts for quick-soak derivatives has
previously been explored using lysozyme test crystals (Nagem
et al., 2001). The use of exceptionally well diffracting test
crystals such as lysozyme in the published test cases for halide
and cation quick-soak derivatization and the use of high
concentrations (1 M) of heavy-atom salts still leaves an
important question unanswered: is this a general technique
which can be used with samples of varying diffraction quality?
Here, we explore a practical example of the use of comple-
mentary cation and anion heavy-atom quick soaks of
moderate ionic strength (300 mM) on a protein crystal of
average diffraction quality, with the MIRAS structure solution
of CYP46A1 at 2.6 A ˚ resolution.
2. Experimental procedures
2.1. Cloning and expression
The (2–50)CYP46A1H4 truncated variant was generated
from the (2–23)CYP46A1H4 expression construct (Mast et
al., 2004) using mutagenic primers and the QuikChange site-
directed mutagenesis kit. The forward 50-primer contained the
initiator Met codon, Ala as the second codon and a sequence
complementary to codons 51–57 (KKDEVGG) of wild-type
CYP46A1. The reverse 30-primer was complementary to the
forward 50-primer. The C-terminal 4 His tag was incorpo-
rated unmodiﬁed from the template sequence. The construct
was transformed into GC5 cells (PGC Scientiﬁcs Corp.) in the
presence of the chaperones GroEL and GroES (Sansen et al.,
2007) and expressed for 48 h at 299 K with shaking at
200 rev min
 1. The expression of P450 and chaperones was
induced with 1 mM isopropyl -d-thiogalactopyranoside and
0.18 g ml
 1 l-arabinose, respectively, 5 h after the overnight
culture had been diluted 100-fold with Terriﬁc Broth medium.
Simultaneously, 0.5 mM -aminolevulinic acid was added to
maximize P450 expression.
2.2. Purification of D(2–50)CYP46A1H4
CYP46A1 was puriﬁed as described previously (Mast et al.,
2004) with several modiﬁcations. Brieﬂy, the harvested
Escherichia coli cells were suspended in 100 mM potassium
phosphate buffer (KPi) pH 7.2 containing 0.2 M KCl, 10 mM
-mercaptoethanol (BME), 10 mM CH-3S and 20% glycerol.
The cell suspension was sonicated on ice using six 20 s pulses
at 1 min intervals and subjected to centrifugation at 106 000g
for 1 h. The supernatant was diluted 1/3-fold with 10 mM KPi
and 20% glycerol and applied onto a DEAE-cellulose column
equilibrated with 75 mM KPi pH 7.2 containing 135 mM KCl,
10 mM BME, 10 mM CH-3S and 20% glycerol. The ﬂow-
through fraction was collected and applied onto Ni-agarose
resin equilibrated with 155 mM KPi pH 7.2 containing 325 mM
KCl, 0.5% CHAPS, 10 mM BME, 10 mM CH-3S, 5 mM
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volumes of equilibration buffer and ﬁve volumes of 50 mM
KPi pH 7.2 containing 0.5% CHAPS, 10 mM BME, 10 mM
CH-3S, 5 mM imidazole and 20% glycerol. The P450 was
eluted with the latter buffer containing 300 mM imidazole and
then diluted tenfold with 50 mM KPi pH 7.2 containing 0.5%
CHAPS, 0.2 mM DTT, 1 mM EDTA, 10 mM CH-3S and 20%
glycerol (the dilution buffer) and applied onto a hydroxy-
apatite column equilibrated with the same buffer. The column
was washed with ten column volumes of the dilution buffer
and the P450 was eluted with the same buffer containing
300 mM KPi. The red-colored fractions were pooled, diluted
tenfold with the dilution buffer and applied onto CM-cellulose
equilibrated with the same buffer. The resin was washed with
ﬁve volumes of the dilution buffer followed by 50 resin
volumes of the same buffer without detergent. The P450 was
eluted with 50 mM KPi pH 7.2 containing 400 mM NaCl,
0.2 mM DTT, 1 mM EDTA, 50 mM CH-3S and 20% glycerol.
The puriﬁed protein was then diluted with 50 mM KPi pH 7.2
containing 0.2 mM DTT, 1 mM EDTA, 50 mM CH-3S and
20% glycerol to decrease the NaCl concentration to 25 mM
and concentrated using an Amicon Ultra centrifugal ﬁlter.
2.3. Crystallization
The complex of (2–50)CYP46A1H4 with CH-3S was
crystallized in Emerald Biosystems clover-leaf sitting-drop
trays. The crystals were grown at 291 K by the sitting-drop
vapour-diffusion method in which 1 mlo fa n 40 mg ml
 1
protein solution (as assessed by the reduced CO-difference
spectrum; Omura & Sato, 1964) in 50 mM KPi pH 7.2, 20%
glycerol, 25 mM NaCl, 1 mM EDTA, 0.2 mM DTTand 50 mM
CH-3S was mixed with an equal volume of 8% PEG 8000,
50 mM KPi pH 4.7 and 20% glycerol. Microseeding with a cat
whisker was then employed to improve the morphology of the
initial crystals. Before ﬂash-cooling in liquid nitrogen, all
crystals were soaked brieﬂy in a cryo-buffer consisting of well
solution with 30% glycerol. Heavy-atom cation and anion
quick-soak salt derivatives were prepared by the addition of
300 mM CsCl or NaI salt to the cryo-buffer (Nagem et al.,
2001).
2.4. Data collection and processing
All data were collected at 105 K using a 100 mm source
MacScience M06X SRA Cu rotating-anode X-ray generator
(Table 1). The 2.6 A ˚ native data, merged from two crystals for
higher redundancy and greater completeness, and those from
the CsCl derivative were collected on a MacScience DIP2030
image-plate detector equipped with MSC Blue confocal optics.
The exposure time roughly matches the image-decay time in
the storage phosphors ( ’ 30 min; White et al., 1999) and the
oscillation range of 0.5  was selected to maximize collection
efﬁciency while still providing good signal to noise without
ﬁne-slicing (Pﬂugrath, 1999). The NaI-derivative data set was
collected on a Bruker-AXS SMART-2K CCD detector
equipped with XENOCS Fox-2D elliptical optics. The expo-
sure time of 10 min per 0.25  frame is limited by the build-up
of dark current and zingers in the CCD. The Bruker CCD was
used to rapidly screen all of the heavy-atom derivatives and
various cryo-buffers and then to collect a preliminary native
data set to 2.8 A ˚ . The image-plate data were indexed, inte-
grated and scaled using HKL-2000 (Otwinowski & Minor,
1997). All data collected on the CCD were processed using the
PROTEUM suite (Bruker-AXS, Madison, Wisconsin, USA).
Potential heavy-atom derivatives were evaluated via cross-
2
and cross-Rmerge values (Gewirth, 2003) with HKL-2000.
2.5. Structure solution
Phaser (Collaborative Computational Project, Number 4,
1994; McCoy et al., 2005) was used to search for possible
molecular-replacement (MR) solutions. Homology models for
molecular-replacement searches were created using Swiss-
Model (Schwede et al., 2003) based on CYP3A4 (PDB code
1tqn; Yano et al., 2004) and CYP2C8 (PDB code 1pq2; Schoch
et al., 2004). In addition to the homology models, the original
PDB entries were also used in MR searches.
Heavy-atom structure solution, reﬁnement and density
modiﬁcation were carried out using the SOLVE/RESOLVE
program package (Terwilliger & Berendzen, 1999). Initial
veriﬁcation of the SOLVE heavy-atom sites was performed
using isomorphous and anomalous difference cross-Fourier
maps created in XTALVIEW (McRee, 1999b) with the
experimental phases from RESOLVE. TEXTAL (Gopal et al.,
2007) was utilized for automated model building into the
RESOLVE density-modiﬁed maps, while manual model
building was performed using Coot (Emsley & Cowtan, 2004)
and XFIT (McRee, 1999b).
2.6. Post-structure solution analysis
Final isomorphous difference cross-Fourier maps and
ﬁgures were generated using phases calculated from the
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Table 1
Crystallographic data and MIRAS statistics.
Values in parentheses are for the highest resolution shell.
Native (Fe) NaI CsCl
Detector DIP2030 SMART 2K DIP2030
No. of frames 194 [ 2] 182 101
Frame width ( ) 0.5 0.25 0.5
Exposure (min) 35 10 35
Net rotation ( ) 97 45.5 50.5
Space group I4122
Unit-cell parameters
a (A ˚ ) 121.73 121.81 121.85
c (A ˚ ) 144.21 143.56 143.94
Resolution 30–2.62 70–2.80 50–2.62
No. of observations 225798 44106 67008
Unique observations 16668 13419 16908
Redundancy 13.4 (6.8) 3.3 (2.1) 4.0 (3.6)
Completeness 99.7 (98) 98.3 (88) 99.4 (92)
Rmerge 13.2 (55) 5.6 (21) 8.7 (49)
I/(I) 9.5 (3.6) 27.7 (4.2) 10 (2.8)
No. of sites 1 14 5
Phasing power 1.0 0.93 0.77
FOM 0.38 (0.10)
FOM after DM 0.67 (0.30)reﬁned 2.6 A ˚ native model. These maps, and A-weighted
2Fo   Fc and Fo   Fc maps from PMB, were viewed in XFIT.
After solving the 2.6 A ˚ resolution structure, the model was re-
reﬁned and a few missing residues were added using a
subsequently obtained 1.9 A ˚ resolution data set collected at
SSRL BL11-1. Detailed analysis of this structure (PDB code
2q9g) will be reported elsewhere, but it is used here in the
analysis of the heavy-atom structures instead of the less
accurate 2.6 A ˚ native structure.
The heavy-atom-containing models were reﬁned against the
derivative data using default PMB techniques (Singh et al.,
2006; Scott et al., 2004), such as variable- B-factor restraints
(Tickle et al., 1998) and stereochemical bond-length variation
targets. PMB, a suite of utilities and CNS patches for semi-
automated structure reﬁnement using CNS, is available from
the author MAW via the WWW (http://xray.utmb.edu/PMB).
No water molecules were modelled owing to the limited
resolution. The individual occupancies of the heavy-atom sites
were reﬁned after resetting their B factors to the average
protein value (I, 40 A ˚ 2;C s ,4 5A ˚ 2). However, at this resolution
the occupancy and B factors are highly correlated.
3. Results and discussion
3.1. Crystallization and crystal morphology
Many proteins, including most P450s, are stabilized by the
binding of a substrate or inhibitor molecule. Cocrystallization
with a ligand will frequently aid in the crystallization of a
protein. Therefore, CYP46A1 was puriﬁed and crystallized in
the presence of the tight-binding substrate analogue CH-3S.
Cocrystals of CYP46A1 and CH-3S grew within two weeks
from microseeded sitting drops. The crystals appeared as
clusters of rectangular rods of approximately 40 mm in width
and 300 mm in length (Fig. 1). The CYP46A1–CH-3S crystals
diffracted to  2.6 A ˚ on a Cu K home source and were found
to belong to the tetragonal space group I4122, with unit-cell
parameters a = b = 121.7, c = 144.2 A ˚ . The Matthews coefﬁ-
cient (Matthews, 1962) of 2.3 A ˚ 3 Da
 1 indicated that the
crystal had one molecule per ASU and a solvent content of
47%.
3.2. Molecular replacement and derivative screening
Molecular replacement was attempted with several models,
using two closely related PDB structures and homology
models based on them. None of these MR searches produced
a solution. The conformational ﬂexibility of the P450s can
make structure solution by MR problematic. Therefore, at this
point we decided to proceed with a strategy that had proven
successful in our previous CYP2B4 structure solution (Scott et
al., 2004): the use of NaI anionic halide salt derivatization. In
addition to the NaI derivative, a cation heavy-atom salt deri-
vative, CsCl, was also screened. This choice was based on our
experience using various monovalent cation and anion solu-
tions for phasing. Other commonly used heavy-atom
compounds of Pt and Hg were screened at the same time and
none were found to produce a useable heavy-atom derivative.
We did not attempt to use the Fe position, determined using
an anomalous difference Patterson map, to boot-strap an MR
solution. We felt that the time and effort spent in obtaining
derivative data and an unbiased experimentally phased
electron-density map via the quick-soak method is signiﬁ-
cantly less than that required to rebuild a poor MR solution.
In a post-structure-solution analysis, the best MR search
model, a Swiss-Model homology model based on CYP3A4,
had a 4.7 A ˚ C
 r.m.s.d. to the ﬁnal CYP46A1 structure,
although the C
 r.m.s.d. to the palm domain (residues 290+)
was only 2 A ˚ .
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Figure 1
Typical tetragonal crystals of CYP46A1. The long tetragonal rods are
approximately 40 mm in width and 300 mm in length. The red color is
typical of the cytochrome P450s and is the consequence of optical
absorbance by the haem prosthetic group. The cytochrome P450 46A1
packs in space group I4122 with the c axis parallel to the long axis of the
rods.
Figure 2
The isomorphous and anomalous differences {
2 ’ [I/(I)]
2} from the
three derivatives. The NaI (purple) and CsCl (green) derivatives both
have a large solvent contribution at very low resolution. At the Cu K
wavelength the anomalous Fe signal (red) is smaller than either of the
isomorphous differences. The NaI data were limited to 2.8 A ˚ resolution
by the detector geometry. The 
2 values were calculated in SCALEPACK
using 30 bins from 30 to 2.6 A ˚ .3.3. MIRAS structure solution
Data were collected to 2.6 A ˚ resolution from two native
crystals and a CsCl quick-soak derivative crystal (Table 1).
The NaI quick-soak derivative crystal data were limited to
2.8 A ˚ resolution by the detector geometry. The structure was
then solved using the MIRAS technique in SOLVE. The weak
anomalous signal from the haem iron was combined with the
isomorphous differences from the two heavy-atom salt soaks
(NaI and CsCl). Although the anomalous signal from the iron
(f0 ’  1.1 and f00 ’ 3.2 at the Cu K wavelength) was weaker
than the isomorphous differences for either the NaI or CsCl
soaks (f ’ 36 for I and f ’ 40 for Cs) based on the 
2
statistic (Fig. 2), the anomalous Patterson map showed clear
and strong peaks (Figs. 3a and 3b). The isomorphous differ-
ence Patterson maps for the two salt derivatives also displayed
strong peaks (Figs. 3c and 3d). Even though the 
2 values for
the caesium and iodide derivatives are signiﬁcantly greater
than that of the iron anomalous data, their isomorphous
difference Patterson maps are noisier with many weak peaks,
requiring automated peak-search algorithms, while the Fe
anomalous difference Patterson could be solved by inspection.
The (300 mM) NaI and CsCl derivatives were nearly
isomorphous to the low ionic strength native crystal (25 mM
NaCl) without the addition of NaCl to its cryo-buffer to create
an isoionic strength buffered native crystal. The NaI derivative
displayed a strong anomalous and isomorphous derivative
signal as measured by the 
2 statistic in SCALEPACK, with
an overall isomorphous difference 
2 of 28. The CsCl deri-
vative also had a moderately good signal, with an overall
isomorphous difference 
2 of 8.4. The anomalous (Bijvoet)
differences in the native data showed a small but signiﬁcant
signal at low resolution, with an overall Bijvoet pair 
2 of only
1.9 (Fig. 2). However, the phasing power of the iron was
signiﬁcantly higher than that of either isomorphous derivative
(Table 1) and the phasing power of the iodide derivative was
signiﬁcantly higher than that of the caesium derivative.
The heavy-atom structure solution in SOLVE found the
single iron site, 14 iodide sites and ﬁve caesium sites. The iron
site was treated as a separate derivative using the native data
and was reﬁned by the anomalous signal alone, while the Cs
and I sites were reﬁned using only the isomorphous differ-
ences, because the anomalous signals of all the data have a
signiﬁcant contribution from the haem iron. However, the
anomalous signal from each of the isomorphous derivatives
was used in the phase calculations. The anomalous and
isomorphous difference signals of the data all become insig-
niﬁcant beyond about 3 A ˚ resolution (Fig. 2) owing to the
lower signal to noise of the high-resolution data. However, all
data collected to about 2.6 A ˚ resolution are useful in the
structure-solution process when solvent ﬂattening is used to
improve and to extend the phases to the limit of the data.
The observed decrease in the isomorphous difference
signals with resolution (Fig. 2) arising from the resolution-
dependence of the atomic scattering factors and the
measurement accuracy is consistent with expectations. The
small but slightly elevated 
2 values in the highest resolution
bins is an indication that the derivatives are not completely
isomorphous to the native crystal. Non-isomorphism, the
effect of which increases with resolution (Garman & Murray,
2003), will result in signiﬁcant intensity differences in all
resolution bins. This measurement of the isomorphism of the
derivatives is a more reliable initial indicator than the cell-
dimension changes alone, as the accuracy of the cell dimen-
sions determined by typical protein crystallography programs
is limited and may not be indicative of changes in protein
conformation or orientation within the cell. The resolution-
dependence of F is a better measure of isomorphism and
should be examined once a full data set has been collected
(McRee, 1999a). Note that at very low resolution both the
cation and anion derivatives have a large erroneous signal
from differences in their solvent scattering, a problem
inherent to the quick-soak procedure. This effect is not
observed in traditional heavy-atom derivatives that are back-
soaked (Garman & Murray, 2003) and which use signiﬁcantly
lower heavy-atom concentrations than either anion or cation
quick soaks.
3.4. Analysis of the heavy-atom sites
In contrast to traditional single-compound heavy-atom
derivatives, both of the derivatives and the native crystal each
contained the anomalously scattering haem iron. The anom-
research papers
Acta Cryst. (2008). D64, 487–495 White et al.   Cytochrome P450 46A1 491
Figure 3
Patterson maps. These are xy Harker sections showing the asymmetric
unit. Bijvoet difference Patterson maps at (a) z = 0.5 and (b) z = 0.25 are
shown for the native data. Isomorphous difference Patterson maps at
z = 0.5 are shown for (c) the NaI and (d) the CsCl quick-soak derivatives,
respectively. Maps are contoured starting at 3 in 0.5 steps. Predicted
Patterson peaks are labelled with a cross; observed peaks are labelled
with the atom name. The iron anomalous and caesium isomorphous
difference maps are at 2.6 A ˚ resolution, while the iodide isomorphous
derivative map is limited to 2.8 A ˚ resolution. The origin peak at (1/2, 1/2,
1/2) has been removed.alous signal from the iron (f00 ’ 3.4 e at Cu K) was exploited
as a single anomalous-only derivative using the native data.
The Fe atom is tightly bound to the protein and is present as a
single copy per ASU or eight Fe atoms per unit cell. Reﬁne-
ment of the B factor, but not the occupancy (which is assumed
to be one), in CNS showed that the tightly bound iron had a
low B factor, much lower than the average protein B factor
(Table 2). The high occupancy and low B factor means that
even the relatively low anomalous signal available from a
single Fe atom per 500 residues still makes a useful contri-
bution to phasing (Fig. 2). In contrast, the heavy atoms in the
salt-derivative soaks are not tightly bound to the protein; they
are dynamic and are loosely bound on the protein surface
(Fig. 4). Their occupancies vary in a rough continuum from a
maximum of 1.0 to zero occupancy (Table 2). The iodide ions
can ﬁnd many surface-binding sites of signiﬁcant afﬁnity
(Fig. 4). In the case of CYP46A1, SOLVE found 14 iodide
sites with occupancies ranging from about one to a lower limit
of  0.2. The dynamic nature of surface-binding residues is
also mirrored in the B-factors of the halide
ions, which are higher than that of the
average protein atom. The caesium deriva-
tive had a slightly higher overall B factor
than the iodide derivative. However, it is the
lower caesium occupancies, in concert with
the lower number of sites (ﬁve), that
combined to reduce the phasing power of
the caesium derivative relative to those of
the iron and iodide derivatives.
An examination of the dual nature
(Evans & Bricogne, 2002) of the iodide-
binding sites is informative as to why there
are more sites for the iodide derivative than
there are for the caesium derivative. Iodide
can bind to either solvent-exposed basic
residues or in hydrophobic pockets (Figs. 5a
and 5b) and in addition to having extensive
hydrophobic interactions frequently forms at least one
hydrogen bond. In the CYP46A1 iodide derivative, four of the
14 iodides were observed without any bonding partners
(Fig. 5b). Other derivative salts seem to require more than one
bonding partner, such as a carbonyl or carboxylate group in
the case of caesium ions. The caesium-ion sites in CYP46A1
typically required three ordered oxygen-binding partners
(Fig. 5a). The coordination of the caesium seems to be less
than ideal, as in most cases the occupancy is much lower than
that observed for the iodide sites. Another factor favouring
the NaI derivative is the protein pI. CYP46A1 is a basic
protein (pI 9.1) with many more basic sites suitable for anion
binding than acidic sites available for cations. It is interesting
to note that the initial halide-ion test crystals were also basic
proteins (Dauter et al., 2000; Nagem et al., 2003). The role of
protein pI in halide binding has not been extensively explored.
However, our experience with Langat virus E protein domain
III (pI 7.0) has shown that halide ions are still a useful deri-
vative at lower protein pIs (White et al., 2003). Based on
solution chemical properties, Nagem and coworkers suggested
that the pH of the buffer solution may also be important. The
binding of cation salts may be favoured at high buffer pH,
while the anion salts were observed to be favoured at lower
pH values.
3.5. Implication of results for the phasing of other systems
When evaluating a potential derivative, there are several
critical items to consider. What makes a good derivative and
why do the apparently large signals not correspond to phasing
power? Heavy atoms that are bound tightly to the protein,
such as a Hg bound to a cysteine, the Fe of a haem or a
selenium incorporated into a methionine, will produce strong
sharp Patterson peaks. The loosely bound solvent atoms of a
cation or anion quick soak, with their moderate occupancy
and higher than average B factors, will have smaller and much
more diffuse Patterson peaks (Buerger, 1959; Dauter &
Dauter, 2001). The difference in the solvent scattering
between the native and the quick-soak derivative is also a
research papers
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Figure 4
Complementary cation and anion heavy-atom salt-derivative sites. Cross-eyed stereoview of
the incomplete N-to-C-termini rainbow-colored CYP46A1 protein backbone and heavy-atom
sites (colored spheres: I, purple; Cs, green) showing the nearby interacting residues as sticks.
This ﬁgure was created using PyMOL (DeLano, 2003).
Table 2
Crystallographic reﬁnement of heavy-atom sites.
Native (Fe) NaI CsCl
Occupancy B (A ˚ 2) Occupancy† B (A ˚ 2) Occupancy† B (A ˚ 2)
Protein 1.00 48 1.00 40 1.00 46
Fe 1.00 26 1.00 21 1.00 28
Site 1 0.97 48 0.34 52
Site 2 0.71 50 0.30 52
Site 3 0.68 53 0.26 63
Site 4 0.65 53 0.21 52
Site 5 0.62 49 0.20 60
Site 6 0.52 53
Site 7 0.52 49
Site 8 0.49 51
Site 9 0.47 57
Site 10 0.47 53
Site 11 0.46 58
Site 12 0.42 60
Site 13 0.37 57
Site 14 0.22 58
† Occupancy and B factors are correlated (see x2.6).major source of non-isomorphism or noise (Fig. 2), even
though the protein and crystal lattice are less likely to be
affected by the soaking (assuming an isoionic strength buffer).
Solvent contributions can be signiﬁcant at 3–4 A ˚ resolution
(Afonine et al., 2005) and will affect both anomalous and
isomorphous differences. In addition, the SIR/MIR(AS)
techniques suffer from inter-crystal differences, such as
absorption, differential solvent contrast and classical crystal
non-isomorphism (lattice changes and protein rearrange-
ment), which are not present in the single-crystal MAD and
SAD methods. This was amply demonstrated in our case,
where an apparently weak (SAD) anomalous signal from a
well ordered Fe provided superior phasing power to the
demonstrably stronger (MIRAS) isomorphous differences
from the iodide and caesium quick soaks. However, the
protein structure could not be solved with any one derivative
alone.
Although this structure was solved on a ﬁxed-wavelength
home source, the general technique is applicable to synchro-
tron radiation using a modiﬁed MAD, SAD or enhanced
MIRAS technique. Either lighter heavy-atom salts that have
accessible absorption edges can be used, such as NaBr and
RbCl, or in the enhanced MIRAS and SAD methods the
X-ray wavelength can be chosen to provide increased anom-
alous signal from the CsCl and NaI salts.
The simultaneous use of anion–cation heavy-atom salts
(RbBr) has been considered as a possible tool for MAD
structure solution (MAW, personal communication). This
multiple-wavelength multiple anomalous scatterer diffraction
(MMAD) technique offers the possibility of creating two
perfectly isomorphous anomalous derivatives, thereby
increasing the number of sites and also the anomalous signal
for phasing. The CYP46A1 structure solution provides an
example of an overlapping cation and anion site near Asn444
and there is another location near Arg76 where the iodide and
caesium sites are in close proximity (Fig. 5). This would have a
negative impact on the expected anomalous signal when using
the MMAD technique. In a mixed heavy-atom soak these sites
could either have low occupancy of both anomalous species or
favour a single species. In either case the anomalous signal for
phasing would be reduced in comparison with separate deri-
vatives. In general, for these reasons mixed heavy-atom soaks
such as CsI or RbBr may be less advantageous than separate
derivatives.
Which technique is better when using anion and cation
quick soaks, Cs/I MIRAS or Rb/Br MAD? Given their large
anomalous and isomorphous (fCu
00 ’ 7, f ’ 40) difference
signals, higher atomic number salts, such as Cs and in parti-
cular I with its dual nature, may provide superior phasing
power when using either MIRAS or possibly even SAD than
the strong anomalous signal from the lighter heavy-atom salts
Rb and Br, which have accessible absorption edges suitable
for MAD or SAD (Br, f0 =  8.3, f00 = 3.8 at 13 474 eV; Rb,
f0 =  10.4, f00 = 3.8 at 15 200 eV). The ability to solve struc-
tures quickly using only a readily available home source is an
advantage of the Cs/I salts with their large f values.
However, when crystal-to-crystal non-isomorphism is a
problem then it may be easier to solve the structure with data
from a single crystal using either the MAD or SAD technique.
3.6. General application of complementary salt derivatives
When using the MIR(AS) technique, cell non-isomorphism
can be a major impediment to structure solution. This problem
research papers
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Figure 5
(a) Superposition of the 2.6 and 2.8 A ˚ isomorphous difference cross-
Fourier maps contoured at 3 showing the interaction of caesium (green)
or iodide (purple) ions with the corresponding CYP46A1 model (yellow
or brown, respectively). Interactions are displayed as green dashes. Close
caesium and iodide sites are observed near Arg76, which has moved in
the NaI model (brown) and makes a contribution to the isomorphous
difference signal (magenta mesh). The third interaction of Cs4, with the
carbonyl of Asn388, is obscured in this view. (b) View of a twofold
crystallographic symmetry-generated protein interface. The iodide (I8)
sits on the twofold axis, ﬂanked by four symmetry-related lysine side
chains and two symmetry-related glycerol (GOL) molecules; the
symmetry-generated molecules are colored lavender. This is one of four
iodide sites that lacks hydrogen bonds; the lysine N
–I distance is 6 A ˚ .
This ﬁgure was drawn using XFIT/RASTER3D (Merritt & Bacon, 1997).is exacerbated in the quick-soak method by the high ionic
strength of the heavy-atom salts. Osmotic stress-induced
crystal damage can be reduced by lowering the salt concen-
tration, but at the expense of phasing power. A possible
solution to this problem is to use isoionic strength crystal
buffers by the addition of similar salt concentrations to each
condition: cation heavy atom (CsCl), anion heavy atom (NaI)
and native (NaCl). This isoionic strength buffer technique was
applied in a recent MIRAS structure solution of the closed
form of CYP2B4 (Scott et al., 2004). In this example, the cryo-
buffer for the native 2B4 crystal contained 300 mM NaCl and
a single NaI derivative was prepared by replacing the NaCl
with the isoionic strength heavy-atom quick-soak cryo-buffer
containing 300 mM NaI. The importance of using isoionic
strength buffers was demonstrated recently in the 1.4 A ˚
SIRAS structure solution of Schizosaccahromyces pombe
Pop2p deadenylase subunit (Jonstrup et al., 2007). When the
native proved to be non-isomorphous with either derivative,
the CsCl quick-soak derivative was used as an isomorphous
‘native’ to ﬁnd the iodide sites in the NaI derivative. It is not
known whether isoosmotic strength or isoionic strength solu-
tions are better at reducing crystal non-isomorphism. In the
case of monovalent salts this distinction is irrelevant as both
are proportional to the salt concentration.
In other cases, we have titrated halide salts up to the
maximum concentration permitted by the crystal before non-
isomorphism or mosaicity (crystal damage) became proble-
matic. With crystals of Langat virus E protein domain III
crystallized in 1.8 M ammonium sulfate (White et al., 2003), we
were able to titrate up to 250 mM KI, simultaneously reducing
the ammonium sulfate to 1.6 M, while still maintaining the
crystal’s suitability as an isomorphous derivative. This was a
difﬁcult problem because the sulfate ions formed bridging
crystal contacts that were disrupted at higher halide salt
concentrations. This case represents the lowest concentration
of halide salt we have used to obtain an isomorphous deri-
vative, but does not necessarily represent the lowest concen-
tration that will produce a useful derivative: the successful
SAD structure solution of SOD was accomplished with only a
200 mM NH4I crystallization solution (Yogavel et al., 2007).
We have demonstrated the basic application of both Cs
cation and I anion heavy-atom salts as traditional MIR(AS)
derivatives. The structure of CYP46A1 with CH-3S bound in
the active site has been determined to 2.6 A ˚ by the MIRAS
method using complementary cation and anion salt quick
soaks. This demonstrates the applicability of the quick-soak
technique in the practical case of a moderately well diffracting
crystal. Given the simplicity and ease of applying this method,
it is recommended as a routine approach to be tried whenever
attempting a MIR(AS) structure solution. Heavy-atom salt
quick soaks can also be used to rescue a poor MAD or SAD
solution (Evans & Bricogne, 2002; Nagem et al., 2003).
3.7. Final CYP46A1 structure refinement
New CYP46A1–CH-3S data were collected to 1.9 A ˚ reso-
lution at SSRL BL11-1 and reﬁnement of the preliminary
2.6 A ˚ model against these high-resolution data has been
performed. The details of the reﬁnement and analysis of the
1.9 A ˚ structure of CYP46A1–CH-3S (PDB code 2q9f) will be
reported elsewhere.
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